Abstract Title:

L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?

Abstract Source:

Int J Cardiol. 2007 Apr 4;116(3):300-8. Epub 2006 Jul 24. PMID: 16860889

Abstract Author(s):

Gerasimos Siasos, Dimitris Tousoulis, Charalambos Antoniades, Elli Stefanadi, Christodoulos Stefanadis

Article Affiliation:

Cardiology Unit, Hippokration Hospital, Athens University Medical School, S. Karagiorga 69, Glifada, 16 675, Athens, Greece.

Abstract:

L-Arginine is the substrate of endothelial nitric oxide synthase (eNOS) and the main precursor of nitric oxide (NO) in the vascular endothelium. L-Arginine improves endothelial function in patients with hypercholesterolemia, hypertension and smokers, while its role in diabetes remains unclear. Oral supplementation of L-arginine leads to a significant improvement of endothelium-dependent forearm vasodilation in hypercholesterolemic patients, while intravenous infusion of L-arginine improves endothelial function in healthy smokers. L-Arginine has anti-hypertensive properties, although its effects on endothelial function in hypertensive patients needs further evaluation. In conclusion, L-arginine administration may be useful in patients with premature atherosclerosis.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.